- Previous Close
411.40 - Open
419.95 - Bid 399.45 x --
- Ask 401.35 x --
- Day's Range
393.05 - 419.95 - 52 Week Range
364.25 - 659.00 - Volume
4,578 - Avg. Volume
6,963 - Market Cap (intraday)
65.352B - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
24.01 - EPS (TTM)
16.72 - Earnings Date May 27, 2025 - May 31, 2025
- Forward Dividend & Yield 10.00 (2.51%)
- Ex-Dividend Date Nov 22, 2024
- 1y Target Est
--
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India.
www.fdcindia.com6,659
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: FDC.BO
View MorePerformance Overview: FDC.BO
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FDC.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FDC.BO
View MoreValuation Measures
Market Cap
64.95B
Enterprise Value
59.12B
Trailing P/E
23.87
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.16
Price/Book (mrq)
2.83
Enterprise Value/Revenue
2.86
Enterprise Value/EBITDA
14.03
Financial Highlights
Profitability and Income Statement
Profit Margin
13.20%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
20.78B
Net Income Avi to Common (ttm)
2.74B
Diluted EPS (ttm)
16.72
Balance Sheet and Cash Flow
Total Cash (mrq)
5.91B
Total Debt/Equity (mrq)
0.88%
Levered Free Cash Flow (ttm)
--